Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.44 |
| ▸ | PRCP | P42785 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956419 | 1.00 | KDM1A (0.51) | KDM1AL3MBTL1RECQLTRPM8PRCP | |
| SCHEMBL3956423 | 1.00 | KDM1A (0.51) | KDM1AL3MBTL1RECQLTRPM8PRCP | |
| SCHEMBL4061572 | 0.84 | PRCP (0.59) | KDM1ARECQLTRPM8PRCPHTR2C | |
| SCHEMBL29561967 | 0.84 | PRCP (0.59) | KDM1ARECQLTRPM8PRCPHTR2C | |
| SCHEMBL22784268 | 0.84 | PRCP (0.59) | KDM1ARECQLTRPM8PRCPHTR2C | |
| SCHEMBL21063709 | 0.81 | PRCP (0.59) | KDM1ARECQLPRCPHTR2CGAA | |
| SCHEMBL3957475 | 0.80 | L3MBTL1 (0.49) | KDM1AL3MBTL1RECQLTRPM8HTR2C | |
| SCHEMBL3966031 | 0.80 | L3MBTL1 (0.49) | KDM1AL3MBTL1RECQLTRPM8HTR2C | |
| SCHEMBL4062159 | 0.80 | PRCP (0.47) | KDM1ARECQLPRCPGAARAB9A | |
| SCHEMBL4063542 | 0.80 | KDM1A (0.50) | KDM1AL3MBTL1RECQLTRPM8PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | KDM1A 3375/4885L3MBTL1 4623/4885RECQL 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.